FASCO Recipients for this quarter – Part 1
FASCO Recipients – Part 1
ASCO recently shared on X:
“Join us in congratulating our members who earned the Fellows of ASCO (FASCO) distinction this quarter! We’re grateful for their extraordinary volunteer service, dedication, and commitment to ASCO.
Learn more about FASCO distinction.”
Part 1 of the list of the doctors who received the FASCO distinction:
Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK). Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies and in particular hepatobiliary cancers.
Professor Abou-Alfa serves on the steering committee of the NCI AIDS Malignancy Consortium, and also serves on steering committee of the International Affairs Committee of the American Society of Clinical Oncology (ASCO).
Prof. Fredrick Chite Asirwa M.D. is the CEO of International Cancer Institute, a not- for-profit organization whose main purpose is to expand Education, Clinical Care and Training opportunities in cancer control and research across sub-Saharan Africa (SSA).
Dr. Asirwa is a Medical Oncologist and Hematologist, PD/PI of several access to personalized cancer care and research initiatives including Blueprint Program (Kenya, Rwanda, Tanzania, Burundi, and Uganda), Shining Tower Program, Clinical Trials Program-all geared towards enhancing early detection, promoting primary HPV screening, providing SOC diagnostics and therapeutics cancer research.
Maria T Bourlon is an Associate Professor and Head of the Urologic Oncology Clinic at National Institute of Medical Sciences and Nutrition Salvador Zubirán, Mexico. She is the Director of the Genitourinary Cancers Program at National Autonomous University of Mexico.
Dr. Bourlon is the chair-elect of the American Society of Clinical Oncology IDEA Steering Group and in 2023 received the prestigious ASCO CCF International Women Who Conquer Cancer (WWCC) Mentorship Award. She is on the Editorial Board of OncoDaily.
Riccardo Braglia serves in the role of chief executive officer and group vice chairman of the board at Helsinn Group in Lugano, Switzerland. He is a member of the Conquer Cancer Foundation. He founded New Flower in Africa Foundation to support education in many countries of Africa sub-Sahara. Mr. Braglia’s personal interests include art collecting and scuba diving.
Barbara Burtness, MD is Professor of Medicine (Medical Oncology) at the Yale School of Medicine, Chief Translational Research Officer, and Associate Cancer Center Director for Translational Research at the Yale Cancer Center. She chairs the ECOG-ACRIN Cooperative Group Head and Neck Cancer Therapeutics Committee and the ECOG-ACRIN Task Force for the Advancement of Women.
John C. Byrd serves as the Chair of the Department of Internal Medicine at the University of Cincinnati. He holds the Gordon and Helen Hughes Taylor Chair. He was previously at The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute where he served as Senior Advisor for Cancer Experimental Therapeutics and Distinguished University Professor.
Dr. Byrd has over 600 publications in the area of leukemia and experimental therapeutics research. He runs a highly translational laboratory focused on CLL and drug development in hematologic malignancies.
Timothy Cannon is and Co-Director of the Gastrointestinal Cancer Program at Inova. He is a specialty care physician board certified in medical oncology. Dr. Cannon is the clinical director and moderator of the weekly molecular tumor board at Inova.
Dr. Cannon is chair-elect of the steering committee for the TAPUR trial, which is the largest oncology basket trial in North America. He also served as the chief fellow of hematology/oncology at New York University (NYU).
Higinia Cardenes is a Radiation Oncologist at Weill Cornell Medicine. She has been a Professor of Radiation Oncology with an adjunct position as Professor of Clinical Obstetrics and Gynecology at Indiana University. She specialises in treating patients with gynecological gastrointestinal cancers.
Jamie Chaft is a thoracic medical oncologist. She practices primarily in New York, NY, and is affiliated with Memorial Sloan Kettering Cancer Center. Dr. Chaft graduated from NYU Grossman School of Medicine in 2006, and completed her training at NY Presby-Cornell and Memorial Sloan Kettering Cancer Center. She is board certified in Internal Medicine and Medical Oncology.
Susan Chang is UCSF Neurosurgery Network Director of Quality, Director of UCSF Neuro-Oncology Gordon Murray Caregiver Program and Co-Director, Sheri Sobrato Brain Cancer Survivorship Program. Dr. Chang is an internationally recognized leader in the field of neurological malignancies. She specializes in the treatment of adults with brain tumors, including glioblastomas and meningioma.
Fumiko Ladd Chino is an attending in Radiation Oncology at MD Anderson Cancer Center, who specializes in gynecological and breast cancers. She was also a caregiver for her husband Andrew Mark Ladd, PhD who died from cancer in 2007.
She is a recipient of numerous awards, including ASCO Excellence in Equity Award (2022), Duke Radiation Oncology Award for Outstanding Clinical Research (2019), Duke University Hospital “Good Catch” Award (2018), Conquer Cancer Foundation of ASCO Merit Award (2018), Duke University School of Medicine Dean’s Recognition Award (2014) and Memorial Hermann Hospital, Texas Medical Center Volunteer of the Year Award (2009).
Julia Close, MD is a professor of medicine in the Division of Hematology and Oncology at the University of Florida. She is the Associate Dean of Graduate Medical Education and the Designated Institutional Official (DIO) for the University of Florida College of Medicine.
She is a clinician educator, with research interest in curriculum related to general oncology and interactions with patients at the end of life. She is actively nationally in education, serving on the American Society of Clinical Oncology (ASCO)’s Professional Development Committee.
Jennie Robertson Crews, is the Associate Chief Medical Officer, Ambulatory Care at Stanford Health Care. She is also the Chief Medical Officer at Stanford Medicine Partners. She is a Clinical Professor in the Department of Medicine, Division of Oncology at Stanford University School of Medicine. Previously she was medical director of the affiliate network program and medical director of research integration for Seattle Cancer Care Alliance (SCCA).
Suzanne Dahlberg is an Associate Professor, Pediatrics at Harvard Medical School and Assistant Director of Clinical Trial Biostatistics and Data Management at Boston Children’s Hospital. Her collaborative work focuses primarily in lung cancer with investigators in the Thoracic Oncology Program at DFCI and as the primary statistician for the Eastern Cooperative Oncology Group’s Thoracic Committee.
Her independent research is in the areas of masked cause failure time data, clinical trial design, and novel analyses of lung cancer data, with a particular interest in comorbidities of lung cancer patients.
Dr. Michael Diaz is an oncologist and hematologist for Florida Cancer Specialists and Research Institute (FCS) in Pinellas County. He serves as the Director of Patient Advocacy and Federal Legislative Committee Chair for the Florida Society of Clinical Oncology (FLASCO), as well as being a Past President. Dr. Diaz has a deep interest in treating breast, lung, colorectal, gastrointestinal, genitourinary, skin, and blood and bone marrow malignancies.
Maximilian Diehn is Scientific Co-Founder of Foresight Diagnostics Inc. He is a member of American Society for Therapeutic Radiology and Oncology (ASTRO), Radiological Society of North America and International Society for Stem Cell Research (ISSCR). He is a Professor at Stanford University School of Medicine.
Martin J. Edelman is the Chair of Department of Hematology/Oncology and Associate Cancer Center Director for Clinical Research Integration at Fox Chase Cancer Centre. He is also the chair of Department of Medical Oncology at Lewis Katz School of Medicine at Temple University.
He specialises in thoracic medical oncology. He has a particular interest in approaches that integrate surgery, radiation, and chemotherapy in the management of lung cancer patients.
Laura Goff, MD, MSCI, is a medical oncologist who specializes in gastrointestinal cancers, particularly hepatobiliary cancers. She is a Professor of Medicine in the Division of Hematology and Oncology, Department of Medicine, at Vanderbilt University Medical Center.
She has been a member of the American Society of Clinical Oncology Professional Development Committee, Education Committee and Scientific Program Committee.
Dr. Haddad’s current research activity involves the use of concurrent and sequential chemoradiotherapy regimens for patients with locally advanced and metastatic head and neck cancer. Dr. Haddad is a member of several professional societies, including the American Society of Clinical Oncology, American Association for Cancer Research, European Society of Medical Oncology , and the American Society for Therapeutic Radiology and Oncology.
Dr. Kalinsky serves as the director of the Glenn Family Breast Center at Winship where he is tasked with fulfilling the vision to improve breast cancer outcomes by aligning research and education with cancer treatment and prevention.
A breast cancer physician and investigator, Dr. Kalinsky’s research focus is in developing new therapeutic approaches to patients with breast cancer. Dr. Kalinsky’s research is in the area of new drug development and therapies for patients with early stage and metastatic breast cancer.
Primo N. Lara, Jr., MD, is the director of the National Cancer Institute–designated UC Davis Comprehensive Cancer Center, leading a team of more than 300 scientists serving more than 10,000 new adult and pediatric patients yearly.
As director, Dr. Lara holds the Codman-Radke Chair in Cancer Research and will serve as executive associate dean for cancer programs. Dr. Lara is active in medical education and training, serving as principal investigator of the NCI-funded K12 Paul Calabresi Clinical Oncology Training Grant, which trains junior faculty scholars to be independent, patient-oriented cancer researchers.
Professor Michael Jefford is a Consultant Medical Oncologist at the Peter MacCallum Cancer Centre. He serves as the Director of the Australian Cancer Survivorship Centre and leads the Survivorship and Living Well After Cancer research program with the Department of Health Services Research. He is also a Professorial Fellow at the University of Melbourne.
Alexia Iasonos is an attending biostatistician at Memorial Sloan Kettering Cancer Centre. She is also involved in vaccine trials as a second line therapy in ovarian cancer patients, and in identifying valid endpoints for these trials.
Her methodological interests focus on model-based designs that guide the dose escalation in phase I trials and in the past few years she has focused on the design of early phase trials that involve dose expansion cohorts.
Abdul Rahman Jazieh is the Chairman in the Department of Oncology and a Professor at King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia. He is the founding Director of the MENA Center for NCCN Collaboration, Ministry of National Guard Health Affairs, Riyadh Saudi Arabia. Previously, he was Professor of Medicine and Chief of Hematology Oncology Division at University of Cincinnati.
Dr. Jazieh is a member of multiple professional societies including former Chairman of the International Affair Committee of American Society of Clinical Oncology (ASCO).
Tricia L. Kalwar is an oncologist in Fort Lauderdale, Florida and is affiliated with multiple hospitals in the area, including Broward Health Medical Center and Broward Health North. She received her medical degree from St. Matthew’s University.
Mark Lewis is the Director of Gastrointestinal Oncology at Intermountain Healthcare in Utah, the Co-Chair of adolescent and young adult (AYA) oncology in the SWOG cooperative group, and the Vice President of American Multiple Endocrine Neoplasia Support. Dr. Lewis is also a well-known patient advocate and social media influencer. His interests are neuroendocrine tumors and cancer syndromes.
Jasmine Kamboj, MD, is a Medical Oncologist and Hematologist at Mayo Clinic, Rochester. Dr Kamboj finished her fellowship in Medical Oncology and Hematology at Baylor College of Medicine in Houston. She has also served on the ASCO Climate Task Force and has contributed to the tremendous work done by the Task Force.
Dr. Kamboj serves on ASCO’s Government Relations Committee and has served on ASCO’s Health Equity and Outcomes committee, Rural Task Force and Clinical Trials Task Force as well. She has been the recipient of the, “Advocate of the Year Award,” in 2021 by ASCO for her advocacy and equity work and has been name in the President’s Circle in 2022.
Gretchen G. Kimmick, MD, MS, is a medical oncologist within the Duke University Health System specializing in the treatment of breast cancer. Dr. Kimmick’s research focuses on the management of menopausal symptoms, survivorship issues, supportive care, and the treatment of older people diagnosed with breast cancer, among other areas. She completed her fellowship in Medical Oncology from Wake Forest University Baptist Medical Center.
For more information about FASCO awardees, click here.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023